Organisation paid for research Program year 2025 Source: CMS Open Payments

Broward Research Center

Neither a doctor nor a teaching hospital

Research payments

$1,239,618

437 payments

Through program year 2025, Broward Research Center is reported as receiving $1,239,618 in research payments, across 437 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $29,283 4
2024 Research $18,909 5
2023 Research $535,932 123
2022 Research $514,351 278
2021 Research $112,333 8
2020 Research $8,934 10
2019 Research $19,875 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Applied Therapeutics, inc. $912,295 391 payments
  2. AstraZeneca Pharmaceuticals LP $242,456 11 payments
  3. Amgen Inc. $39,756 23 payments
  4. Genentech, Inc. $29,225 7 payments
  5. Sanofi US Services Inc. $13,856 1 payment
  6. Pfizer Inc. $2,030 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy $912,295 391 payments
  2. AMETHYST Congestive Heart Failure CHF Heart Failure Therapy Area Cardiovascular, Renal and Metabolism $141,098 5 payments
  3. This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio $101,358 6 payments
  4. Roche Cancer Screening Collection Study $29,225 7 payments
  5. Galactic-Hf $16,858 5 payments
  6. A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype $13,856 1 payment
  7. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) $9,617 1 payment
  8. Galactic - HF $7,662 6 payments
  9. FDA Mandated Sample Collection $3,548 4 payments
  10. Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure (METEORIC-HF) $1,720 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record